Podema Sp. z o.o.

The research conducted at Podema Sp. z o.o. addresses serious bacterial infections of the lower extremity, particularly diabetic foot infections. A primary aim is to compare the safety and effectiveness of contezolid with established treatments such as linezolid in patients with moderate to severe infections. The studies also monitor systemic tolerability and overall clinical response to these antimicrobial strategies.

• Comparative antibiotic efficacy for diabetic foot infections
• Safety and tolerability profiling of new oral and IV agents
• Investigator-assessed clinical response at defined follow‑up visits
• Outcomes related to infection resolution and patient recovery

Located in Warsaw, Poland, the site has launched two investigator‑led trials with a dedicated team of two clinicians, focusing on advancing treatment options for bacterial foot complications.

At this clinic, attention is directed toward chronic skin conditions such as diabetic foot ulcers, aiming to improve wound healing through innovative topical therapies. Researchers evaluate the safety, tolerability, and healing rates of the investigational product AUP1602‑C applied in different dosing schedules compared with standard care. The goal is to achieve complete wound closure and enhance quality of life for patients with non‑healing ulcers.

• Topical antimicrobial treatment for non‑healing diabetic foot ulcers
• Assessment of local and systemic safety in ulcer patients
• Measurement of total wound closure rates across dosing regimens
• Evaluation of patient‑reported outcomes and ulcer recurrence

The Warsaw‑based facility supports these investigations with a focused clinical team, contributing to the broader effort to advance care for skin and connective tissue disorders.